Janssen’s Imbruvica (ibrutinib) has racked up two positive recommendations from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), it has been revealed.
While CHMP opinions are not binding, they are usually followed when it comes to passing a final verdict on whether to approve a product for market, meaning Imbruvica could soon see its label expanded.
